Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Brief description of study

The purpose of the study is to determine the safety and efficacy of the study drugs called vemurafenib and cobimetinib. We want to know if genes can be affected in craniopharyngiomas and have found mutations or changes in the gene called BRAF. When BRAF is altered, it can cause a tumor to grow. In this study, the goal is to see if Vemurafenib and cobimetinib could shrink your tumor by at least one-quarter compared to its present size.

Clinical Study Identifier: s19-01872 Identifier: NCT03224767
Principal Investigator: Sylvia C. Kurz.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.